CytoMed Therapeutics Limited (GDTC) Total Return Calculator with Dividends Reinvested

CytoMed Therapeutics Limited

Popular:

The total return for CytoMed Therapeutics Limited (GDTC) stock is -57.69% over the past 12 months. So far it's down 28.78% this year. The 5-year total return is -75.25%, meaning $10,000 invested in GDTC stock 5 years ago would be worth $2,475 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in GDTC 1 year ago, it would be worth $4,533 today — you'd have lost $5,467.

With Dividends Reinvested$4,533-54.67%

Price Only (No DRIP)$4,533-54.67%

Period2025-06-30 → 2026-06-26

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in GDTC

1Y$4,231-$5,769 (-57.7%)-57.7% CAGR

3Y$3,449-$6,551 (-65.5%)-29.9% CAGR

5Y$2,475-$7,525 (-75.3%)-24.4% CAGR

10Y$2,475-$7,525 (-75.3%)-13.0% CAGR

15Y$2,475-$7,525 (-75.2%)-8.9% CAGR

20Y$2,475-$7,525 (-75.3%)-6.7% CAGR

30Y$2,475-$7,525 (-75.2%)-4.5% CAGR

CytoMed Therapeutics Limited did not pay dividends during this period. Total return = price return.

Loading GDTC total return...

As of 2026-06-28

Performance Summary

Best Year+22.50%2023

Worst Year-61.86%2025

Max Drawdown-73.12%2025-10-20 → 2026-05-07

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-28.78%	—	-26.62%	—	$7,122
1Y	-57.69%	-57.69%	-55.65%	—	$4,231
3Y	-65.51%	-29.87%	-64.46%	—	$3,449
5Y	-75.25%	-24.37%	-74.50%	—	$2,475
10Y	-75.25%	-13.03%	-74.50%	—	$2,475
15Y	-75.25%	-8.89%	-74.50%	—	$2,475
20Y	-75.25%	-6.74%	-74.50%	—	$2,475
30Y	-75.25%	-4.55%	-74.50%	—	$2,475

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-22.30%	-22.30%	—	+0.41%	-22.7pp
2025	-61.86%	-61.86%	—	+16.64%	-78.5pp
2024	-22.90%	-22.90%	—	+24.00%	-46.9pp
2023	+22.50%	+22.50%	—	+24.81%	-2.3pp

GDTC underperformed the S&P 500 by 78.53pp over the past year (-57.69% vs +20.84%).

Loading summary...

GDTC Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
GDTCCytoMed Therapeutics Limited	$12M	-11.3%	-28.8%	-57.7%	—	-65.5%	-75.3%	-75.3%
FATEFate Therapeutics, Inc.	$245M	-2.3%	+108.1%	+76.1%	—	-58.6%	-97.6%	+9.0%
NKTRNektar Therapeutics	$1.2B	-2.9%	+49.5%	+165.4%	—	+621.1%	-74.6%	-69.9%
CELCCelcuity Inc.	$4.9B	-25.6%	-4.1%	+693.3%	—	+691.3%	+216.1%	+574.5%
IOVAIovance Biotherapeutics, Inc.	$1.5B	+3.7%	+68.5%	+125.8%	—	-43.6%	-83.7%	-46.0%
TGTXTG Therapeutics, Inc.	$8.5B	+40.5%	+83.1%	+43.7%	—	+134.4%	+38.1%	+785.9%
CRSPCRISPR Therapeutics AG	$5.3B	+6.5%	-0.4%	+14.5%	—	-4.8%	-61.2%	+280.1%
NTLAIntellia Therapeutics, Inc.	$1.9B	+32.3%	+68.3%	+62.0%	—	-63.0%	-82.2%	-40.8%
BEAMBeam Therapeutics Inc.	$3.6B	+16.9%	+24.9%	+97.7%	—	+6.0%	-63.9%	+80.8%
EDITEditas Medicine, Inc.	$279M	-7.5%	+36.6%	+24.4%	—	-65.0%	-93.1%	-89.3%
ALNYAlnylam Pharmaceuticals, Inc.	$38.9B	-1.4%	-26.5%	-9.5%	—	+53.7%	+69.3%	+441.4%

Compare:GDTC vs FATE GDTC vs NKTR GDTC vs CELC GDTC vs FATE vs NKTR

About GDTC Dividend Returns

CytoMed Therapeutics Limited (GDTC) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of GDTC over the past year?

CytoMed Therapeutics Limited (GDTC) delivered a return of -57.69% over the past year. Since GDTC does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in GDTC be worth today?

A $10,000 investment in CytoMed Therapeutics Limited one year ago would be worth $4,231 today, representing a loss of $5,769.

Q3Does GDTC pay dividends?

CytoMed Therapeutics Limited (GDTC) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For GDTC, the total return equals the price-only return.

Q4Did GDTC beat the S&P 500?

No, CytoMed Therapeutics Limited (GDTC) underperformed the S&P 500 by 78.53 percentage points over the past year. GDTC delivered a total return of -57.69%, compared to the S&P 500's 20.84%. This means a passive S&P 500 index fund outperformed GDTC by 78.53pp during this period.

Q5What is GDTC's worst drawdown?

CytoMed Therapeutics Limited (GDTC) experienced a maximum drawdown of -73.12% over the past year, declining from its peak on 2025-10-20 to its trough on 2026-05-07. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is GDTC's long-term total return over 10, 20, or 30 years?

Here are CytoMed Therapeutics Limited (GDTC)'s long-term returns with dividends reinvested. Over 10 years, the total return is -75.3% (-13.0% CAGR) — $10,000 would have grown to $2,475. Over 20 years: -75.3% total return (-6.7% CAGR) — $10,000 → $2,475. Over 30 years: -75.2% total return (-4.5% CAGR) — $10,000 → $2,475. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was GDTC's best and worst year?

CytoMed Therapeutics Limited's best calendar year was 2023 with a total return of 22.5%. Its worst year was 2025 with a total return of -61.9%. This range shows the volatility investors should expect — the difference between the best and worst year is 84.4 percentage points.

How much would $100/month in GDTC be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →